RT Journal Article
SR Electronic
T1 Pancytopenia in a patient treated with fusidic acid and niraparib: a case report
JF European Journal of Hospital Pharmacy
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP ejhpharm-2021-002819
DO 10.1136/ejhpharm-2021-002819
A1 Margaux Damerval
A1 Fernando Bazan
A1 Selim Omrani
A1 Marion Hugues
A1 Marie-Françoise Roux
A1 Joséphine Mayer
YR 2022
UL http://ejhp.bmj.com/content/early/2022/02/28/ejhpharm-2021-002819.abstract
AB Fusidic acid is an antibiotic used in the treatment of staphylococcal infections. Niraparib is an anticancer drug indicated for the treatment of advanced ovarian cancer. The interaction between these two drugs has not been studied and is not referenced in drug databases. We present the case of a patient with pancytopenia who had been treated with fusidic acid and niraparib. No other treatment was taken by this patient. According to the literature, both substances can cause haematological toxicity. It seems unlikely that this is due to niraparib alone because it had been well tolerated by the patient for over a year before the pancytopenia was diagnosed. It was also perfectly well tolerated when it was reintroduced. We cannot determine whether this pancytopenia is due to fusidic acid alone or to a drug interaction between the two treatments. We therefore recommend caution in patients treated with this combination.All data relevant to the study are included in the article.